


FLULAVAL Tetra

inactivated influenza vaccine (2023-24)
quadrivalent, standard dose

≥ 6 months[‡]

DIN 02420783



SUPPLIED:
multidose vial



PREPARATION:
ready-to-use;
do not dilute



ADMINISTRATION:
IM injection



APPROPRIATE
USE:

- 6 months and older[‡]
- < 9 years old — confirm no influenza vaccine in last 28 days



BEYOND-USE
EXPIRY
DATE/TIME:

- Check date on label (expiry date)
- Unpunctured: 2°C to 8°C: use vaccine until expiry date
- Punctured: 2°C to 8°C: use vaccine within 28 days of first puncture



HANDLING:

- SHAKE before withdrawing each dose



APPEARANCE:

- Opalescent translucent to off-white suspension, may sediment slightly
- NO particulate matter/discolouration



DOSE:

0.5 mL

Children < 9 years old who have not previously received seasonal influenza vaccine require 2 doses given at least 4 weeks apart

[‡] Pharmacy professionals can immunize those 5 years and older

REFERENCES:

- FluLaval Tetra (2023-2024). Product monograph. GlaxoSmithKline Inc.; 2023. Accessed September 14, 2023. https://pdf.hres.ca/dpd_pm/00072445.PDF

FLULAVAL Tetra

inactivated influenza vaccine (2023-24)
quadrivalent, standard dose

≥ 6 months[‡]

DIN 02420783



SUPPLIED:
multidose vial



PREPARATION:
ready-to-use;
do not dilute



ADMINISTRATION:
IM injection



APPROPRIATE
USE:

- 6 months and older[‡]
- < 9 years old — confirm no influenza vaccine in last 28 days



BEYOND-USE
EXPIRY
DATE/TIME:

- Check date on label (expiry date)
- Unpunctured: 2°C to 8°C: use vaccine until expiry date
- Punctured: 2°C to 8°C: use vaccine within 28 days of first puncture



HANDLING:

- SHAKE before withdrawing each dose



APPEARANCE:

- Opalescent translucent to off-white suspension, may sediment slightly
- NO particulate matter/discolouration



DOSE:

0.5 mL

Children < 9 years old who have not previously received seasonal influenza vaccine require 2 doses given at least 4 weeks apart

[‡] Pharmacy professionals can immunize those 5 years and older

REFERENCES:

- FluLaval Tetra (2023-2024). Product monograph. GlaxoSmithKline Inc.; 2023. Accessed September 14, 2023. https://pdf.hres.ca/dpd_pm/00072445.PDF